News
March 11, 2025
Sunbird Bio Appoints Vijay Parthasarathy, Ph.D., MBA, as Chief Product and Strategy Officer
January 8, 2025
Sunbird Bio Appoints Richard Batrla, M.D., Ph.D., MBA as Chief Medical Officer
October 31, 2024
Sunbird Bio Presents New Clinical Data Demonstrating Proprietary Alpha Synuclein Blood-Based Biomarkers Could Accurately Diagnose Parkinson’s Disease
October 16, 2024
Sunbird Bio Raises Additional $14 Million to Advance Broadest Blood-Based Diagnostic Platform in Alzheimer’s Disease and Other Neurological Disorders
July 28, 2024
Sunbird Bio Presents Latest Data Reinforcing Significance of Blood-Based Tau Biomarkers in the Accurate Diagnosis of Alzheimer’s Disease
July 11, 2024
Sunbird Bio to Present Data from Study Evaluating Tau Blood-Based Biomarkers at the Alzheimer’s Association International Conference® 2024 (AAIC®)
March 25, 2024
New Findings From Sunbird Bio Reveal Significant Potential of Specific Tau Proteins to Serve as Blood-Based Biomarker for Alzheimer’s Disease
March 13, 2024
Sunbird Bio to Present Findings From Study Assessing Key Alzheimer’s Disease Biomarker at the Tau2024 Global Conference
March 5, 2024
New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood
February 21, 2024
Sunbird Bio to Present Positive Data from APEX Alzheimer’s Disease Diagnostic Platform at AD/PD™ 2024
August 9, 2023
Sunbird Bio Merges with Glympse Bio to Accelerate Development of Proprietary Protein-Based Diagnostic Technologies